{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:05:39Z","timestamp":1784196339499,"version":"3.55.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-026-05034-2","type":"journal-article","created":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T12:54:08Z","timestamp":1769950448000},"page":"3291-3303","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anticoagulation approaches in hemodialysis: a systematic review of efficacy, safety, and literature gap"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3544-9355","authenticated-orcid":false,"given":"Areej I.","family":"Alhazmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,1]]},"reference":[{"key":"5034_CR1","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2407185","volume":"24","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Wang Y (2023) Management of cardiovascular diseases in chronic hemodialysis patients. Rev Cardiovasc Med 24:185. https:\/\/doi.org\/10.31083\/j.rcm2407185","journal-title":"Rev Cardiovasc Med"},{"key":"5034_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cardfail.2022.09.013","volume":"29","author":"MS Khan","year":"2022","unstructured":"Khan MS, Ahmed A, Greene SJ, Fiuzat M, Kittleson MM, Butler J, Bakris GL, Fonarow GC (2022) Managing heart failure in patients on dialysis: state-of-the-art review. J Card Fail 29:87\u2013107. https:\/\/doi.org\/10.1016\/j.cardfail.2022.09.013","journal-title":"J Card Fail"},{"key":"5034_CR3","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jsps.2015.01.009","volume":"24","author":"AM Shaman","year":"2015","unstructured":"Shaman AM, Kowalski SR (2015) Hyperphosphatemia management in patients with chronic kidney disease. Saudi Pharm J 24:494\u2013505. https:\/\/doi.org\/10.1016\/j.jsps.2015.01.009","journal-title":"Saudi Pharm J"},{"key":"5034_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s40885-023-00240-x","volume":"29","author":"IS Kim","year":"2023","unstructured":"Kim IS, Kim S, Yoo TH, Kim JK (2023) Diagnosis and treatment of hypertension in dialysis patients: a systematic review. Clin Hypertens 29:24. https:\/\/doi.org\/10.1186\/s40885-023-00240-x","journal-title":"Clin Hypertens"},{"issue":"Suppl. S3","key":"5034_CR5","doi-asserted-by":"publisher","first-page":"112","DOI":"10.5005\/jp-journals-10071-23412","volume":"24","author":"S Singh","year":"2015","unstructured":"Singh S (2015) Anticoagulation during renal replacement therapy. Indian J Crit Care Med 24(Suppl. S3):112\u2013116. https:\/\/doi.org\/10.5005\/jp-journals-10071-23412","journal-title":"Indian J Crit Care Med"},{"key":"5034_CR6","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/sdi.12380","volume":"28","author":"M Kessler","year":"2015","unstructured":"Kessler M, Moureau F, Nguyen P (2015) Anticoagulation in chronic hemodialysis: progress toward an optimal approach. Semin Dial 28:474\u2013489. https:\/\/doi.org\/10.1111\/sdi.12380","journal-title":"Semin Dial"},{"key":"5034_CR7","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1053\/j.ajkd.2012.03.017","volume":"60","author":"JI Shen","year":"2012","unstructured":"Shen JI, Winkelmayer WC (2012) Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis. Am J Kidney Dis 60:473\u2013486. https:\/\/doi.org\/10.1053\/j.ajkd.2012.03.017","journal-title":"Am J Kidney Dis"},{"key":"5034_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/medsci12030038","volume":"12","author":"PHF Gois","year":"2024","unstructured":"Gois PHF, McIntyre D, Ratanjee S, Pelecanos A, Scuderi C, Janoschka CL, Summers K, Wu H, Elford B, Ranganathan D et al (2024) Hemodialysis without systemic anticoagulation: a randomized controlled trial to evaluate five strategies in patients at a high risk of bleeding. Med Sci 12:38. https:\/\/doi.org\/10.3390\/medsci12030038","journal-title":"Med Sci"},{"key":"5034_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd011858.pub2","volume":"2024","author":"P Natale","year":"2024","unstructured":"Natale P, Palmer SC, Ruospo M, Longmuir H, Dodds B, Prasad R, Batt TJ, Jose MD, Strippoli GF (2024) Anticoagulation for people receiving long-term haemodialysis. Cochrane Database Syst Rev 2024:CD011858. https:\/\/doi.org\/10.1002\/14651858.cd011858.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"5034_CR10","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/j.1523-1755.2005.00468.x","volume":"68","author":"F Ziai","year":"2005","unstructured":"Ziai F, Benesch T, Kodras K, Neumann I, Dimopoulos-Xicki L, Haas M (2005) The effect of oral anticoagulation on clotting during hemodialysis. Kidney Int 68:862\u2013866. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00468.x","journal-title":"Kidney Int"},{"key":"5034_CR11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.cvsm.2010.12.001","volume":"41","author":"S Ross","year":"2011","unstructured":"Ross S (2011) Anticoagulation in intermittent hemodialysis: pathways, protocols, and pitfalls. Vet Clin North Am Small Anim Pract 41:163\u2013175. https:\/\/doi.org\/10.1016\/j.cvsm.2010.12.001","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"5034_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2023.151473","volume":"43","author":"MM Engelen","year":"2023","unstructured":"Engelen MM, Verhamme P, Vanassche T (2023) Clotting of the extracorporeal circuit in hemodialysis: beyond contact-activated coagulation. Semin Nephrol 43:151473. https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151473","journal-title":"Semin Nephrol"},{"key":"5034_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2024.109120","volume":"242","author":"C Jessica","year":"2024","unstructured":"Jessica C, Kevin V, Marie VA, Marica B, Maria CM, Emanuel F, Liberato C, Nicoletta R, Alexander G (2024) A comparative study on the haemostatic changes in kidney failure patients: pre- and post- haemodialysis and haemodiafiltration. Thromb Res 242:109120. https:\/\/doi.org\/10.1016\/j.thromres.2024.109120","journal-title":"Thromb Res"},{"key":"5034_CR14","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s12882-019-1527-3","volume":"20","author":"D Ashby","year":"2019","unstructured":"Ashby D, Borman N, Burton J, Corbett R, Davenport A, Farrington K, Flowers K, Fotheringham J, Fox RNA, Franklin G et al (2019) Renal association clinical practice guideline on haemodialysis. BMC Nephrol 20:379. https:\/\/doi.org\/10.1186\/s12882-019-1527-3","journal-title":"BMC Nephrol"},{"key":"5034_CR15","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/j.1525-139x.2010.00770.x","volume":"23","author":"RE Cronin","year":"2010","unstructured":"Cronin RE, Reilly RF (2010) Unfractionated heparin for hemodialysis: still the best option. Semin Dial 23:510\u2013515. https:\/\/doi.org\/10.1111\/j.1525-139x.2010.00770.x","journal-title":"Semin Dial"},{"key":"5034_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111561","volume":"139","author":"M Qiu","year":"2021","unstructured":"Qiu M, Huang S, Luo C, Wu Z, Liang B, Huang H, Ci Z, Zhang D, Han L, Lin J (2021) Pharmacological and clinical application of heparin progress: an essential drug for modern medicine. Biomed Pharmacother 139:111561. https:\/\/doi.org\/10.1016\/j.biopha.2021.111561","journal-title":"Biomed Pharmacother"},{"key":"5034_CR17","doi-asserted-by":"publisher","DOI":"10.1177\/10760296231177993","author":"R Hamadi","year":"2023","unstructured":"Hamadi R, Sakr F, Aridi H, Alameddine Z, Dimachkie R, Assaad M, Asmar S, ElSayegh S (2023) Heparin-induced thrombocytopenia in chronic hemodialysis patients. Clin Appl Thromb Hemost. https:\/\/doi.org\/10.1177\/10760296231177993","journal-title":"Clin Appl Thromb Hemost"},{"key":"5034_CR18","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/jth.13312","volume":"14","author":"K Chandarajoti","year":"2016","unstructured":"Chandarajoti K, Liu J, Pawlinski R (2016) The design and synthesis of new synthetic low-molecular-weight heparins. J Thromb Haemost 14:1135\u20131145. https:\/\/doi.org\/10.1111\/jth.13312","journal-title":"J Thromb Haemost"},{"key":"5034_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/1477-9560-4-6","volume":"4","author":"E Arbit","year":"2006","unstructured":"Arbit E, Goldberg M, Gomez-Orellana I, Majuru S (2006) Oral heparin: status review. Thromb J 4:6. https:\/\/doi.org\/10.1186\/1477-9560-4-6","journal-title":"Thromb J"},{"key":"5034_CR20","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1055\/s-2001-17961","volume":"27","author":"B Boneu","year":"2001","unstructured":"Boneu B, De Moerloose P (2001) How and when to monitor a patient treated with low molecular weight heparin. Semin Thromb Hemost 27:519\u2013522. https:\/\/doi.org\/10.1055\/s-2001-17961","journal-title":"Semin Thromb Hemost"},{"key":"5034_CR21","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/clc.23196","volume":"42","author":"V Aursulesei","year":"2019","unstructured":"Aursulesei V, Costache II (2019) Anticoagulation in chronic kidney disease: from guidelines to clinical practice. Clin Cardiol 42:774\u2013782. https:\/\/doi.org\/10.1002\/clc.23196","journal-title":"Clin Cardiol"},{"key":"5034_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-023-00576-2","volume":"22","author":"S Ma","year":"2024","unstructured":"Ma S, Fan G, Xu F, Zhang X, Chen Y, Tao Y, Li Y, Lyu Y, Yang P, Wang D et al (2024) Efficacy and safety of anticoagulant for treatment and prophylaxis of VTE patients with renal insufficiency: a systemic review and meta-analysis. Thromb J 22:17. https:\/\/doi.org\/10.1186\/s12959-023-00576-2","journal-title":"Thromb J"},{"key":"5034_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare13121373","volume":"13","author":"F Parul","year":"2025","unstructured":"Parul F, Ratnani T, Subramani S, Bhatia H, Ashmawy RE, Nair N, Manchanda K, Anyagwa OE, Kaka N, Patel N et al (2025) Anticoagulation in patients with end-stage renal disease: a critical review. Healthcare 13:1373. https:\/\/doi.org\/10.3390\/healthcare13121373","journal-title":"Healthcare"},{"key":"5034_CR24","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/mcp.0b013e328216430d","volume":"13","author":"M Crowther","year":"2007","unstructured":"Crowther M, Lim W (2007) Low molecular weight heparin and bleeding in patients with chronic renal failure. Curr Opin Pulm Med 13:409\u2013413. https:\/\/doi.org\/10.1097\/mcp.0b013e328216430d","journal-title":"Curr Opin Pulm Med"},{"key":"5034_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1261183","volume":"10","author":"JAL Mapili","year":"2023","unstructured":"Mapili JAL, Lim LCS, Velando BM, Aherrera JAM (2023) The safety and efficacy of direct oral anticoagulants among chronic kidney disease patients on dialysis with non-valvular atrial fibrillation: a meta-analysis. Front Cardiovasc Med 10:1261183. https:\/\/doi.org\/10.3389\/fcvm.2023.1261183","journal-title":"Front Cardiovasc Med"},{"key":"5034_CR26","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2017:11:2","volume":"12","author":"S Julia","year":"2017","unstructured":"Julia S, James U (2017) Direct oral anticoagulants: a quick guide. Eur Cardiol Rev 12:40. https:\/\/doi.org\/10.15420\/ecr.2017:11:2","journal-title":"Eur Cardiol Rev"},{"key":"5034_CR27","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.tcm.2023.11.005","volume":"34","author":"P Niehues","year":"2023","unstructured":"Niehues P, Wolfes J, Wegner FK, Ellermann C, Rath B, Eckardt L (2023) Use of direct oral anticoagulants in patients on chronic hemodialysis: contemporary appraisal on the role for patients with atrial fibrillation. Trends Cardiovasc Med 34:446\u2013450. https:\/\/doi.org\/10.1016\/j.tcm.2023.11.005","journal-title":"Trends Cardiovasc Med"},{"key":"5034_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14092914","volume":"14","author":"G Miceli","year":"2025","unstructured":"Miceli G, Ciaccio AM, Tuttolomondo A (2025) Challenges and opportunities of direct oral anticoagulant (DOAC) therapy in complex clinical scenarios: a comprehensive review and practical guide. J Clin Med 14:2914. https:\/\/doi.org\/10.3390\/jcm14092914","journal-title":"J Clin Med"},{"key":"5034_CR29","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.21608\/ijma.2024.251147.1873","volume":"5","author":"A Abdelrahem","year":"2024","unstructured":"Abdelrahem A, Mokarrab M, Abdelfattah A, Abdelghany A (2024) The use of direct oral anticoagulants compared to vitamin K antagonists [Warfarin] in patients with left ventricular thrombus. Int J Med Arts 5:3889\u20133895. https:\/\/doi.org\/10.21608\/ijma.2024.251147.1873","journal-title":"Int J Med Arts"},{"key":"5034_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-42069-2","volume":"13","author":"S Eloot","year":"2023","unstructured":"Eloot S, Vanommeslaeghe F, Josipovic I, Boone M, Van Biesen W (2023) Association between anticoagulation strategy and quality of life in chronic hemodialysis patients. Sci Rep 13:15105. https:\/\/doi.org\/10.1038\/s41598-023-42069-2","journal-title":"Sci Rep"},{"key":"5034_CR31","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.120.017559","volume":"9","author":"A Chen","year":"2020","unstructured":"Chen A, Stecker E, Warden BA (2020) Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc 9:e017559. https:\/\/doi.org\/10.1161\/jaha.120.017559","journal-title":"J Am Heart Assoc"},{"key":"5034_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-024-00608-5","volume":"22","author":"Y Li","year":"2024","unstructured":"Li Y, Wu S, Zhou J, Zhang J (2024) Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation combined with chronic kidney disease: a systematic review and meta-analysis. Thromb J 22:40. https:\/\/doi.org\/10.1186\/s12959-024-00608-5","journal-title":"Thromb J"},{"key":"5034_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40620-024-02130-3","volume":"38","author":"EC Martinez","year":"2024","unstructured":"Martinez EC, Cruz CS, Acosta EYD, Cano DAA, Espinosa AM, Mart\u00ednez DO, Furman F, Vera SO (2024) Efficacy and safety of novel anticoagulant therapies in patients with chronic kidney disease\u2014a systematic review and meta-analysis. J Nephrol 38:111\u2013126. https:\/\/doi.org\/10.1007\/s40620-024-02130-3","journal-title":"J Nephrol"},{"key":"5034_CR34","doi-asserted-by":"publisher","unstructured":"Latif F, Meer KK, Shaikh Z, Mubbashir A, Khan U, Usmani TF, Alvares J, Imran M, Shahid A, Shaikh AW et al (2024) Efficacy of oral anticoagulants in chronic kidney disease and hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis. Deleted J. Online ahead of print. https:\/\/doi.org\/10.23736\/s2724-5683.24.06564-5","DOI":"10.23736\/s2724-5683.24.06564-5"},{"key":"5034_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae270","volume":"17","author":"GH Heine","year":"2024","unstructured":"Heine GH, Schneppe C, Bauersachs R, Eitel I, Neuen BL, Ruff CT, Schirmer SH, De Vriese A (2024) 10 tips to manage oral anticoagulation in hemodialysis patients with atrial fibrillation. Clin Kidney J 17:sfae270. https:\/\/doi.org\/10.1093\/ckj\/sfae270","journal-title":"Clin Kidney J"},{"key":"5034_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02318-8","volume":"23","author":"Q Li","year":"2024","unstructured":"Li Q, Li P, Xu Z, Lu Z, Yang C, Ning J (2024) Association of diabetes with cardiovascular calcification and all-cause mortality in end-stage renal disease in the early stages of hemodialysis: a retrospective cohort study. Cardiovasc Diabetol 23:259. https:\/\/doi.org\/10.1186\/s12933-024-02318-8","journal-title":"Cardiovasc Diabetol"},{"key":"5034_CR37","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s40620-022-01413-x","volume":"35","author":"K Parker","year":"2022","unstructured":"Parker K, Hartemink J, Saha A, Mitra R, Lewis P, Power A, Choudhuri S, Mitra S, Thachil J (2022) A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney disease. J Nephrol 35:2015\u20132033. https:\/\/doi.org\/10.1007\/s40620-022-01413-x","journal-title":"J Nephrol"},{"key":"5034_CR38","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/rth2.12083","volume":"2","author":"D Reed","year":"2018","unstructured":"Reed D, Palkimas S, Hockman R, Abraham S, Le T, Maitland H (2018) Safety and effectiveness of apixaban compared to warfarin in dialysis patients. Res Pract Thromb Haemost 2:291\u2013298. https:\/\/doi.org\/10.1002\/rth2.12083","journal-title":"Res Pract Thromb Haemost"},{"key":"5034_CR39","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.japh.2023.12.020","volume":"64","author":"M Moore","year":"2024","unstructured":"Moore M, Vizcaino K, Ewing JA, St Ville M (2024) Efficacy and safety of apixaban compared to warfarin for nonvalvular atrial fibrillation in end-stage renal disease on hemodialysis. J Am Pharm Assoc 64:457\u2013462. https:\/\/doi.org\/10.1016\/j.japh.2023.12.020","journal-title":"J Am Pharm Assoc"},{"key":"5034_CR40","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/circulationaha.121.054990","volume":"146","author":"SD Pokorney","year":"2022","unstructured":"Pokorney SD, Chertow GM, Al-Khalidi HR, Gallup D, Dignacco P, Mussina K, Bansal N, Gadegbeku CA, Garcia DA, Garonzik S et al (2022) Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial. Circulation 146:1735\u20131745. https:\/\/doi.org\/10.1161\/circulationaha.121.054990","journal-title":"Circulation"},{"key":"5034_CR41","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1161\/circulationaha.122.062779","volume":"147","author":"H Reinecke","year":"2022","unstructured":"Reinecke H, Engelbertz C, Bauersachs R, Breithardt G, Echterhoff H-H, Ger\u00df J, Haeusler KG, Hewing B, Hoyer J, Juergensmeyer S et al (2022) A randomized controlled trial comparing Apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study. Circulation 147:296\u2013309. https:\/\/doi.org\/10.1161\/circulationaha.122.062779","journal-title":"Circulation"},{"key":"5034_CR42","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1681\/asn.2019060579","volume":"31","author":"AS De Vriese","year":"2019","unstructured":"De Vriese AS, Caluw\u00e9 R, Pyfferoen L, De Bacquer D, De Boeck K, Delanote J, De Surgeloose D, Van Hoenacker P, Van Vlem B, Verbeke F (2019) Multicenter randomized controlled trial of vitamin K antagonist replacement by Rivaroxaban with or without vitamin K2 in hemodialysis patients with atrial fibrillation: the Valkyrie study. J Am Soc Nephrol 31:186\u2013196. https:\/\/doi.org\/10.1681\/asn.2019060579","journal-title":"J Am Soc Nephrol"},{"key":"5034_CR43","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1161\/circulationaha.118.035418","volume":"138","author":"KC Siontis","year":"2018","unstructured":"Siontis KC, Zhang X, Eckard A, Bhave N, Schaubel DE, He K, Tilea A, Stack AG, Balkrishnan R, Yao X et al (2018) Outcomes associated with Apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation 138:1519\u20131529. https:\/\/doi.org\/10.1161\/circulationaha.118.035418","journal-title":"Circulation"},{"key":"5034_CR44","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1053\/j.ajkd.2022.03.007","volume":"80","author":"JB Wetmore","year":"2022","unstructured":"Wetmore JB, Weinhandl ED, Yan H, Reyes JL, Herzog CA, Roetker NS (2022) Apixaban dosing patterns versus Warfarin in patients with nonvalvular atrial fibrillation receiving dialysis: a retrospective cohort study. Am J Kidney Dis 80:569-579.e1. https:\/\/doi.org\/10.1053\/j.ajkd.2022.03.007","journal-title":"Am J Kidney Dis"},{"key":"5034_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0249940","volume":"16","author":"YC Lin","year":"2021","unstructured":"Lin YC, Chen BL, Shih CM, Lin F-Y, Chen C-W, Hsu C-Y, Kao Y-T, Bi W-F, Chen L-Y, Chien L-N et al (2021) Effectiveness and safety of rivaroxaban versus warfarin in Taiwanese patients with end-stage renal disease and nonvalvular atrial fibrillation: a real-world nationwide cohort study. PLoS ONE 16:e0249940. https:\/\/doi.org\/10.1371\/journal.pone.0249940","journal-title":"PLoS ONE"},{"key":"5034_CR46","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1161\/circulationaha.114.014113","volume":"131","author":"KE Chan","year":"2015","unstructured":"Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW (2015) Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation 131:972\u2013979. https:\/\/doi.org\/10.1161\/circulationaha.114.014113","journal-title":"Circulation"},{"key":"5034_CR47","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1093\/ckj\/sfad125","volume":"16","author":"R Thielemans","year":"2023","unstructured":"Thielemans R, Vanommeslaeghe F, Josipovic I, De Somer F, Devreese K, Boone M, Van Biesen W, Eloot S (2023) The op-timized anticoagulation strategy in prolonged hemodialysis. Clin Kidney J 16:2235\u20132242. https:\/\/doi.org\/10.1093\/ckj\/sfad125","journal-title":"Clin Kidney J"},{"key":"5034_CR48","doi-asserted-by":"publisher","DOI":"10.31083\/rcm26736","volume":"26","author":"HM De Oliveira","year":"2025","unstructured":"De Oliveira HM, Barros LP, De Campos MCAV, Daher RF, Gon\u00e7alves GB, Sequeira MT, Botelho SM, Junior AdSM (2025) Anticoagulation strategies for atrial fibrillation in CKD stage G5 and dialysis patients: an updated scoping review. Rev Cardiovasc Med 26:26736. https:\/\/doi.org\/10.31083\/rcm26736","journal-title":"Rev Cardiovasc Med"},{"key":"5034_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1009748","volume":"9","author":"M De Troyer","year":"2022","unstructured":"De Troyer M, Wissing KM, De Clerck D, Cambier M-L, Robberechts T, Tonnelier A, Fran\u00e7ois K (2022) Risk for excessive anticoagulation during hemodialysis is associated with type of vascular access and bedside coagulation testing: results of a cross-sectional study. Front Med 9:1009748. https:\/\/doi.org\/10.3389\/fmed.2022.1009748","journal-title":"Front Med"},{"key":"5034_CR50","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/1744-9987.13652","volume":"26","author":"A Santos","year":"2022","unstructured":"Santos A, Mac\u00edas N, Vega A, Abad S, Linares T, Aragoncillo I, Cruzado L, Pascual C, Goicoechea M, L\u00f3pez-G\u00f3mez JM (2022) Expanded hemodialysis: is anticoagulation of the dialysis circuit different from online hemodiafiltration and high-flux hemodialysis? Ther Apher Dial 26:147\u2013153. https:\/\/doi.org\/10.1111\/1744-9987.13652","journal-title":"Ther Apher Dial"},{"key":"5034_CR51","doi-asserted-by":"publisher","DOI":"10.1080\/0886022x.2025.2464830","volume":"47","author":"J Li","year":"2025","unstructured":"Li J, Wang L, Lu Y, Zhou Y, Chen Y (2025) Nafamostat mesylate versus regional citrate anticoagulation for chronic hemodialysis in patients at high risk of bleeding: a single-center, retrospective study. Ren Fail 47:2464830. https:\/\/doi.org\/10.1080\/0886022x.2025.2464830","journal-title":"Ren Fail"},{"key":"5034_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-019-1661-y","volume":"20","author":"T Lin","year":"2019","unstructured":"Lin T, Song L, Huang R, Huang Y, Tang S, Lin Q, Zhang Y, Wu X, Liang H, Wu Y et al (2019) Modified regional citrate anticoagulation is optimal for hemodialysis in patients at high risk of bleeding: a prospective randomized study of three anticoagulation strategies. BMC Nephrol 20:472. https:\/\/doi.org\/10.1186\/s12882-019-1661-y","journal-title":"BMC Nephrol"},{"key":"5034_CR53","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1177\/1076029612463424","volume":"20","author":"K Klejna","year":"2014","unstructured":"Klejna K, Naumnik B, Koc-\u017b\u00f3rawska E, My\u015bliwiec M (2014) Effect of unfractionated and low-molecular-weight heparin on OPG, sRANKL, and von Willebrand factor concentrations during hemodialysis. Clin Appl Thromb Hemost 20:433\u2013441. https:\/\/doi.org\/10.1177\/1076029612463424","journal-title":"Clin Appl Thromb Hemost"},{"key":"5034_CR54","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/hdi.12563","volume":"22","author":"M Murea","year":"2017","unstructured":"Murea M, Russell GB, Daeihagh P, Saran AM, Pandya K, Cabrera M, Burkart JM, Freedman BI (2017) Efficacy and safety of low-dose heparin in hemodialysis. Hemodial Int 22:74\u201381. https:\/\/doi.org\/10.1111\/hdi.12563","journal-title":"Hemodial Int"},{"key":"5034_CR55","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/sdi.12829","volume":"32","author":"RF Reilly","year":"2019","unstructured":"Reilly RF, Jain N (2019) Warfarin in nonvalvular atrial fibrillation\u2014time for a change? Semin Dial 32:520\u2013526. https:\/\/doi.org\/10.1111\/sdi.12829","journal-title":"Semin Dial"},{"key":"5034_CR56","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.nefroe.2024.03.008","volume":"44","author":"E Perez-Bernat","year":"2024","unstructured":"Perez-Bernat E, Vi\u00f1as Ma A, Vera M, Gonz\u00e1lez-Rico M, Montomoli M, Astudillo-Cort\u00e9s E, Quevedo-Reina JC, Garc\u00eda-M\u00e9ndez I, Martinez-Losa A, Rama-Arias I et al (2024) Non-valvular atrial fibrillation in patients on peritoneal dialysis, prevalence, treatment and professionals involved. Nefrol (Engl Ed) 44:268\u2013275. https:\/\/doi.org\/10.1016\/j.nefroe.2024.03.008","journal-title":"Nefrol (Engl Ed)"},{"key":"5034_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.847286","volume":"9","author":"S Elfar","year":"2022","unstructured":"Elfar S, Elzeiny SM, Ismail H, Makkeyah Y, Ibrahim M (2022) Direct oral anticoagulants vs. warfarin in hemodialysis patients with atrial fibrillation: a systematic review and meta-analysis. Front Cardiovasc Med 9:847286. https:\/\/doi.org\/10.3389\/fcvm.2022.847286","journal-title":"Front Cardiovasc Med"},{"key":"5034_CR58","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.nefroe.2022.01.013","volume":"42","author":"C S\u00e1nchez-Gonz\u00e1lez","year":"2022","unstructured":"S\u00e1nchez-Gonz\u00e1lez C, Calvo JAH (2022) Nonvalvular atrial fibrillation in patients undergoing chronic hemodialysis. Should dialysis patients with atrial fibrillation receive oral anticoagulation? Nefrolog\u00eda (English Edition) 42:633\u2013644. https:\/\/doi.org\/10.1016\/j.nefroe.2022.01.013","journal-title":"Nefrolog\u00eda (English Edition)"},{"key":"5034_CR59","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ahj.2015.03.017","volume":"170","author":"SD Pokorney","year":"2015","unstructured":"Pokorney SD, Simon DN, Thomas L, Fonarow GC, Kowey PR, Chang P, Singer DE, Ansell J, Blanco RG, Gersh B et al (2015) Patients\u2019 time in therapeutic range on warfarin among US patients with atrial fibrillation: results from ORBIT-AF registry. Am Heart J 170:141-148.e1. https:\/\/doi.org\/10.1016\/j.ahj.2015.03.017","journal-title":"Am Heart J"},{"key":"5034_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41397-024-00329-y","volume":"24","author":"B Cross","year":"2024","unstructured":"Cross B, Turner RM, Zhang JE, Pirmohamed M (2024) Being precise with anticoagulation to reduce adverse drug reactions: are we there yet? Pharmacogenomics J 24:7. https:\/\/doi.org\/10.1038\/s41397-024-00329-y","journal-title":"Pharmacogenomics J"},{"key":"5034_CR61","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s11096-022-01386-8","volume":"44","author":"AM Fahmi","year":"2022","unstructured":"Fahmi AM, Elewa H, Jilany IE (2022) Warfarin dosing strategies evolution and its progress in the era of precision medicine, a narrative review. Int J Clin Pharm 44:599\u2013607. https:\/\/doi.org\/10.1007\/s11096-022-01386-8","journal-title":"Int J Clin Pharm"},{"key":"5034_CR62","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2509321","volume":"25","author":"Z Guo","year":"2024","unstructured":"Guo Z, Wang Y, Ding X, Lai J, Chen Y (2024) Safety and effectiveness outcomes between apixaban versus vitamin K antagonists in atrial fibrillation patients on dialysis. Rev Cardiovasc Med 25:321. https:\/\/doi.org\/10.31083\/j.rcm2509321","journal-title":"Rev Cardiovasc Med"},{"key":"5034_CR63","doi-asserted-by":"publisher","first-page":"41","DOI":"10.5853\/jos.2024.03923","volume":"27","author":"L Li","year":"2025","unstructured":"Li L, Lioutas VA, Akyea RK, Gerner S, Lau KK, Ramage E, Katsanos AH, Howard G, Bath PM (2025) Non-inferiority trials in stroke research: what are they, and how should we interpret them? J Stroke 27:41\u201351. https:\/\/doi.org\/10.5853\/jos.2024.03923","journal-title":"J Stroke"},{"key":"5034_CR64","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s40256-024-00664-2","volume":"24","author":"SR Mandt","year":"2024","unstructured":"Mandt SR, Thadathil N, Klem C, Russ C, McNamee PL, Stigge K, Cheng D (2024) Apixaban use in patients with kidney impairment: a review of pharmacokinetic, interventional, and observational study data. Am J Cardiovasc Drugs 24:603\u2013624. https:\/\/doi.org\/10.1007\/s40256-024-00664-2","journal-title":"Am J Cardiovasc Drugs"},{"key":"5034_CR65","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.nefroe.2017.04.013","volume":"37","author":"LB Vega","year":"2017","unstructured":"Vega LB, De Francisco \u00c1LM, Da Silva JB, Espinoza LG, Fresnedo GF (2017) New oral anticoagulants in patients with chronic kidney disease. Nefrol 37:244\u2013252. https:\/\/doi.org\/10.1016\/j.nefroe.2017.04.013","journal-title":"Nefrol"},{"key":"5034_CR66","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1093\/ndt\/gfaa351","volume":"36","author":"I Van Den Bosch","year":"2020","unstructured":"Van Den Bosch I, Bouillon T, Verhamme P, Vanassche T, Jacquemin M, Coemans M, Kuypers D, Meijers B (2020) Apixaban in patients on haemodialysis: a single-dose pharmacokinetics study. Nephrol Dial Transplant 36:884\u2013889. https:\/\/doi.org\/10.1093\/ndt\/gfaa351","journal-title":"Nephrol Dial Transplant"},{"key":"5034_CR67","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ipej.2021.04.002","volume":"21","author":"G Murtaza","year":"2021","unstructured":"Murtaza G, Turagam MK, Garg J, Boda U, Akella K, Velagapudi P, Natale A, Gopinathannair R, Lakkireddy D (2021) Safety and efficacy of apixaban versus warfarin in patients with atrial fibrillation or venous thromboembolism and end-stage renal disease on hemodialysis: a systematic review and meta-analysis. Indian Pacing Electrophysiol J 21:221\u2013226. https:\/\/doi.org\/10.1016\/j.ipej.2021.04.002","journal-title":"Indian Pacing Electrophysiol J"},{"key":"5034_CR68","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.thromres.2023.06.027","volume":"229","author":"A Almajdi","year":"2023","unstructured":"Almajdi A, Almutairi S, Alharbi M (2023) Safety and efficacy of apixaban versus low-molecular weight heparin or vitamin-K antagonists for venous thromboembolism treatment in patients with severe renal failure: a systematic review and meta-analysis. Thromb Res 229:77\u201385. https:\/\/doi.org\/10.1016\/j.thromres.2023.06.027","journal-title":"Thromb Res"},{"key":"5034_CR69","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/jcph.628","volume":"56","author":"X Wang","year":"2015","unstructured":"Wang X, Tirucherai G, Marbury TC, Wang J, Chang M, Zhang D, Song Y, Pursley J, Boyd RA, Frost C (2015) Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol 56:628\u2013636. https:\/\/doi.org\/10.1002\/jcph.628","journal-title":"J Clin Pharmacol"},{"key":"5034_CR70","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1016\/j.jacc.2016.02.082","volume":"67","author":"KE Chan","year":"2016","unstructured":"Chan KE, Giugliano RP, Patel MR, Abramson S, Jardine M, Zhao S, Perkovic V, Maddux FW, Piccini JP (2016) Nonvitamin K anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF. J Am Coll Cardiol 67:2888\u20132899. https:\/\/doi.org\/10.1016\/j.jacc.2016.02.082","journal-title":"J Am Coll Cardiol"},{"key":"5034_CR71","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ekir.2024.10.016","volume":"10","author":"NW Lange","year":"2024","unstructured":"Lange NW, Muir J, Salerno DM (2024) Direct oral anticoagulants in patients with ESRD and kidney transplantation. Kidney Int Rep 10:40\u201353. https:\/\/doi.org\/10.1016\/j.ekir.2024.10.016","journal-title":"Kidney Int Rep"},{"key":"5034_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1320939","volume":"14","author":"XF Shen","year":"2023","unstructured":"Shen XF, Zhang C, Hu J, Zhang T, Ma B (2023) Anticoagulant drugs for patients with atrial fibrillation on dialysis: a systematic analysis and network meta-analysis. Front Pharmacol 14:1320939. https:\/\/doi.org\/10.3389\/fphar.2023.1320939","journal-title":"Front Pharmacol"},{"key":"5034_CR73","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.kint.2019.11.027","volume":"97","author":"VK Derebail","year":"2019","unstructured":"Derebail VK, Rheault MN, Kerlin BA (2019) Role of direct oral anticoagulants in patients with kidney disease. Kidney Int 97:664\u2013675. https:\/\/doi.org\/10.1016\/j.kint.2019.11.027","journal-title":"Kidney Int"},{"key":"5034_CR74","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s40620-024-01930-x","volume":"37","author":"EM Nwanosike","year":"2024","unstructured":"Nwanosike EM, Merchant HA, Sunter W, Ansari MA, Conway BR, Hasan SS (2024) A real-world exploration into clinical outcomes of direct oral anticoagulant therapy in people with chronic kidney disease: a large hospital-based study. J Nephrol 37:1227\u20131240. https:\/\/doi.org\/10.1007\/s40620-024-01930-x","journal-title":"J Nephrol"},{"key":"5034_CR75","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k2505","volume":"362","author":"Y Vinogradova","year":"2018","unstructured":"Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J (2018) Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ 362:k2505. https:\/\/doi.org\/10.1136\/bmj.k2505","journal-title":"BMJ"},{"key":"5034_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.684638","volume":"12","author":"R Roberti","year":"2021","unstructured":"Roberti R, Iannone LF, Palleria C, Curcio A, Rossi M, Sciacqua A, Armentaro G, Vero A, Manti A, Cassano V et al (2021) Direct oral anticoagulants: from randomized clinical trials to real-world clinical practice. Front Pharmacol 12:684638. https:\/\/doi.org\/10.3389\/fphar.2021.684638","journal-title":"Front Pharmacol"},{"key":"5034_CR77","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.124.036832","volume":"14","author":"M Yildirim","year":"2025","unstructured":"Yildirim M, Milles BR, Hund H, Biener M, M\u00fcller\u2010Hennessen M, Frey N, Katus HA, Giannitsis E, Salbach C (2025) Outcomes and disease management in patients with atrial fibrillation \u226580 years: data from a consecutive 11-year real-world registry. J Am Heart Assoc 14:e036832. https:\/\/doi.org\/10.1161\/jaha.124.036832","journal-title":"J Am Heart Assoc"},{"key":"5034_CR78","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/jcph.2184","volume":"63","author":"LV Bortman","year":"2022","unstructured":"Bortman LV, Mitchell F, Naveiro S, Morales JP, Gonzalez CD, Di Girolamo G, Giorgi MA (2022) Direct oral anticoagulants: an updated systematic review of their clinical pharmacology and clinical effectiveness and safety in patients with nonvalvular atrial fibrillation. J Clin Pharmacol 63:383\u2013396. https:\/\/doi.org\/10.1002\/jcph.2184","journal-title":"J Clin Pharmacol"},{"key":"5034_CR79","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.kint.2022.06.013","volume":"102","author":"P Rossing","year":"2022","unstructured":"Rossing P, Caramori ML, Chan JCN, Heerspink HJ, Hurst C, Khunti K, Liew A, Michos ED, Navaneethan SD, Olowu WA et al (2022) Executive summary of the KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease: an update based on rapidly emerging new evidence. Kidney Int 102:990\u2013999. https:\/\/doi.org\/10.1016\/j.kint.2022.06.013","journal-title":"Kidney Int"},{"key":"5034_CR80","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40001-024-01660-7","volume":"29","author":"D Liu","year":"2024","unstructured":"Liu D, Zhao J, Xia H, Dong S, Yan S, Zhuang Y, Chen Y, Peng H (2024) Nafamostat mesylate versus regional citrate anticoagulation for continuous renal replacement therapy in patients at high risk of bleeding: a retrospective single-center study. Eur J Med Res 29:72. https:\/\/doi.org\/10.1186\/s40001-024-01660-7","journal-title":"Eur J Med Res"},{"key":"5034_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-021-02248-7","volume":"22","author":"L Andrews","year":"2021","unstructured":"Andrews L, Benken S, Tan X, Wenzler E (2021) Pharmacokinetics and dialytic clearance of apixaban during in vitro continuous renal replacement therapy. BMC Nephrol 22:45. https:\/\/doi.org\/10.1186\/s12882-021-02248-7","journal-title":"BMC Nephrol"},{"key":"5034_CR82","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3390\/jcm13051351","volume":"13","author":"WE Nekidy","year":"2024","unstructured":"Nekidy WE, Abidi E, Nabil S, Kendakji S, Ali M, Aburuz S, Atallah B, Hijazi F, Mallat J, Akour A (2024) The safety and effectiveness of apixaban in patients with end-stage kidney disease on dialysis: a retrospective observational study. J Clin Med 13:1351. https:\/\/doi.org\/10.3390\/jcm13051351","journal-title":"J Clin Med"},{"key":"5034_CR83","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jtha.2023.09.020","volume":"22","author":"A Jones","year":"2023","unstructured":"Jones A, Swan D, Lisman T, Barnes GD, Thachil J (2023) Anticoagulation in chronic kidney disease: current status and future perspectives. J Thromb Haemost 22:323\u2013336. https:\/\/doi.org\/10.1016\/j.jtha.2023.09.020","journal-title":"J Thromb Haemost"},{"key":"5034_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.tru.2025.100210","volume":"20","author":"M Jansson","year":"2025","unstructured":"Jansson M, Sj\u00e4lander S, Sj\u00f6gren V, Bj\u00f6rck F, Renlund H, Sj\u00e4lander A (2025) Clinical outcomes of direct oral anticoagulant off-label dosing in nonvalvular atrial fibrillation. Thromb Update 20:100210. https:\/\/doi.org\/10.1016\/j.tru.2025.100210","journal-title":"Thromb Update"},{"key":"5034_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2024.151517","volume":"44","author":"SL Wing","year":"2024","unstructured":"Wing SL, Mavrakanas TA, Harel Z (2024) Oral anticoagulation use in individuals with atrial fibrillation and chronic kidney disease: a review. Semin Nephrol 44:151517. https:\/\/doi.org\/10.1016\/j.semnephrol.2024.151517","journal-title":"Semin Nephrol"},{"key":"5034_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2023.100675","volume":"5","author":"JT Ha","year":"2023","unstructured":"Ha JT, Scaria A, Andrade J, Badve SV, Birks P, Bota SE, Campain A, Djurdjev O, Garg AX, Harel Z et al (2023) Safety and effectiveness of Rivaroxaban versus Warfarin across GFR levels in atrial fibrillation: a population-based study in Australia and Canada. Kidney Med 5:100675. https:\/\/doi.org\/10.1016\/j.xkme.2023.100675","journal-title":"Kidney Med"},{"key":"5034_CR87","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1517\/17425255.2014.931371","volume":"10","author":"TJ Velenosi","year":"2014","unstructured":"Velenosi TJ, Urquhart BL (2014) Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis. Expert Opin Drug Metab Toxicol 10:1131\u20131143. https:\/\/doi.org\/10.1517\/17425255.2014.931371","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"5034_CR88","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1160\/th14-06-0547","volume":"113","author":"T Marbury","year":"2015","unstructured":"Marbury T, Matsushima N, Chen S, Wickremasingha PK, He L, Dishy V, Brown KS, Parasrampuria DA (2015) Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis. Thromb Haemost 113:719\u2013727. https:\/\/doi.org\/10.1160\/th14-06-0547","journal-title":"Thromb Haemost"},{"key":"5034_CR89","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1161\/circulationaha.111.084996","volume":"125","author":"D Capodanno","year":"2012","unstructured":"Capodanno D, Angiolillo DJ (2012) Antithrombotic therapy in patients with chronic kidney disease. Circulation 125:2649\u20132661. https:\/\/doi.org\/10.1161\/circulationaha.111.084996","journal-title":"Circulation"},{"key":"5034_CR90","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/ejh.13520","volume":"106","author":"C Kato","year":"2020","unstructured":"Kato C, Oakes M, Kim M, Desai A, Olson SR, Raghunathan V, Shatzel JJ (2020) Anticoagulation strategies in extracorporeal circulatory devices in adult populations. Eur J Haematol 106:19\u201331. https:\/\/doi.org\/10.1111\/ejh.13520","journal-title":"Eur J Haematol"},{"key":"5034_CR91","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1161\/circulationaha.123.065614","volume":"148","author":"Y Xu","year":"2023","unstructured":"Xu Y, Chang AR, Inker LA, McAdams-DeMarco M, Grams ME, Shin JI (2023) Associations of Apixaban dose with safety and effectiveness outcomes in patients with atrial fibrillation and severe chronic kidney disease. Circulation 148:1445\u20131454. https:\/\/doi.org\/10.1161\/circulationaha.123.065614","journal-title":"Circulation"},{"key":"5034_CR92","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/joa3.13051","volume":"40","author":"A AlTurki","year":"2024","unstructured":"AlTurki A, Marafi M, Dawas A, Joza J, Proietti R, Russo V, Mavrakanas T, Trinh E, Weber C, Suri R et al (2024) Meta-analysis evaluating apixaban in patients with atrial fibrillation and end-stage renal disease requiring dialysis. J Arrhythm 40:440\u2013447. https:\/\/doi.org\/10.1002\/joa3.13051","journal-title":"J Arrhythm"},{"key":"5034_CR93","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.hrthm.2025.01.045","volume":"22","author":"MJ Wu","year":"2025","unstructured":"Wu MJ, Chen HH, Chen CH, Tsai SF (2025) Effectiveness and safety of Apixaban and Warfarin in patients with new onset atrial fibrillation after advanced chronic kidney disease or end-stage kidney disease. Heart Rhythm 22:1197\u20131209. https:\/\/doi.org\/10.1016\/j.hrthm.2025.01.045","journal-title":"Heart Rhythm"},{"key":"5034_CR94","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/1753944716643645","volume":"10","author":"J Uprichard","year":"2016","unstructured":"Uprichard J (2016) Management of rivaroxaban in relation to bodyweight and body mass index. Ther Adv Cardiovasc Dis 10:294\u2013303. https:\/\/doi.org\/10.1177\/1753944716643645","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"5034_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvsv.2023.07.008","volume":"12","author":"B Wang","year":"2023","unstructured":"Wang B, Wang Q, Ji Y, Zhang Y, Qiao T (2023) The clinical outcomes of different doses of rivaroxaban in patients with isolated distal deep vein thrombosis. J Vasc Surg Venous Lymphat Disord 12:101653. https:\/\/doi.org\/10.1016\/j.jvsv.2023.07.008","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"key":"5034_CR96","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1177\/1076029616631427","volume":"22","author":"D Kubitza","year":"2016","unstructured":"Kubitza D, Berkowitz SD, Misselwitz F (2016) Evidence-based development and rationale for once-daily rivaroxaban dosing regimens across multiple indications. Clin Appl Thromb Hemost 22:412\u2013422. https:\/\/doi.org\/10.1177\/1076029616631427","journal-title":"Clin Appl Thromb Hemost"},{"key":"5034_CR97","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s13181-011-0178-y","volume":"7","author":"M Ganetsky","year":"2011","unstructured":"Ganetsky M, Babu KM, Salhanick SD, Brown RS, Boyer EW (2011) Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol 7:281\u2013287. https:\/\/doi.org\/10.1007\/s13181-011-0178-y","journal-title":"J Med Toxicol"},{"key":"5034_CR98","doi-asserted-by":"publisher","first-page":"E282","DOI":"10.1161\/str.0000000000000407","volume":"53","author":"SM Greenberg","year":"2022","unstructured":"Greenberg SM, Ziai WC, Cordonnier C, Dowlatshahi D, Francis B, Goldstein JN, Hemphill JC, Johnson R, Keigher KM, Mack WJ et al (2022) 2022 guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association\/American Stroke Association. Stroke 53:E282\u2013E361. https:\/\/doi.org\/10.1161\/str.0000000000000407","journal-title":"Stroke"},{"key":"5034_CR99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40119-024-00352-x","volume":"13","author":"J Presume","year":"2024","unstructured":"Presume J, Ferreira J, Ribeiras R (2024) Factor XI inhibitors: a new horizon in anticoagulation therapy. Cardiol Ther 13:1\u201316. https:\/\/doi.org\/10.1007\/s40119-024-00352-x","journal-title":"Cardiol Ther"},{"key":"5034_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152741","volume":"73","author":"AI Celia","year":"2025","unstructured":"Celia AI, Vescovo GM, Sarto G, Alessandri C, Iaconelli A, D\u2019amario D, Frati G, Conti F, Sciarretta S, Angiolillo DJ et al (2025) Direct oral anticoagulants versus vitamin K antagonists in antiphospholipid syndrome: a systematic review and meta-analysis. Semin Arthritis Rheum 73:152741. https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152741","journal-title":"Semin Arthritis Rheum"},{"key":"5034_CR101","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","volume":"81","author":"CD Khairani","year":"2022","unstructured":"Khairani CD, Bejjani A, Piazza G, Jimenez D, Monreal M, Chatterjee S, Pengo V, Woller SC, Cortes-Hernandez J, Connors JM et al (2022) Direct oral anticoagulants vs Vitamin K antagonists in patients with antiphospholipid syndromes. J Am Coll Cardiol 81:16\u201330. https:\/\/doi.org\/10.1016\/j.jacc.2022.10.008","journal-title":"J Am Coll Cardiol"},{"key":"5034_CR102","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12325-022-02333-9","volume":"40","author":"S Ballestri","year":"2022","unstructured":"Ballestri S, Romagnoli E, Arioli D, Coluccio V, Marrazzo A, Athanasiou A, Di Girolamo M, Cappi C, Marietta M, Capitelli M (2022) Risk and management of bleeding complications with direct oral anticoagulants in patients with atrial fibrillation and venous thromboembolism: a narrative review. Adv Ther 40:41\u201366. https:\/\/doi.org\/10.1007\/s12325-022-02333-9","journal-title":"Adv Ther"},{"key":"5034_CR103","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.hrthm.2025.02.009","volume":"22","author":"E Bulh\u00f5es","year":"2025","unstructured":"Bulh\u00f5es E, Antunes VLJ, Alexandre C, Defante ML, Mazetto R, Oliveira VMR, Sousa PA, Guida C, Scanavacca MI, Darrieux F (2025) Efficacy and safety of DOACs versus vitamin K antagonists in patients with atrial fibrillation and chronic kidney disease undergoing hemodialysis: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. Heart Rhythm 22:1210\u20131217. https:\/\/doi.org\/10.1016\/j.hrthm.2025.02.009","journal-title":"Heart Rhythm"},{"key":"5034_CR104","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.85615","volume":"17","author":"H Aman","year":"2025","unstructured":"Aman H, Sikandar A, Dar FK, Shahid Z, Shibu S, Usman M, Abbas N (2025) Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in elderly patients with atrial fibrillation: a systematic review. Cureus 17:e85615. https:\/\/doi.org\/10.7759\/cureus.85615","journal-title":"Cureus"},{"key":"5034_CR105","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s11239-020-02304-3","volume":"51","author":"MV Mariani","year":"2020","unstructured":"Mariani MV, Magnocavallo M, Straito M, Piro A, Severino P, Iannucci G, Chimenti C, Mancone M, Della Rocca DG, Forleo GB et al (2020) Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis. J Thromb Thrombolysis 51:419\u2013429. https:\/\/doi.org\/10.1007\/s11239-020-02304-3","journal-title":"J Thromb Thrombolysis"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05034-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05034-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05034-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:19:06Z","timestamp":1784193546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-026-05034-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":105,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["5034"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05034-2","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,1]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}